RARA CRAFT DATABASE for FDA Medical Devices
510(k)K230557

FDA DEVICE FACTS

Eclipse Treatment Planning System (v18.0)

Varian Medical Systems, Inc.

FDA-sourced product information for medical-device development research. Use the official FDA sources at the end of this page when the original public document wording is needed.医療機器開発の調査用に、FDA の公開情報から取った製品情報を示しています。公開文書の原文が必要なときは、このページの最後にある FDA の公式な出典をご覧ください。

DECISION DATEMay 26, 2023PRODUCT CODEMUJ

Indications for use

The Eclipse Treatment Planning System (Eclipse TPS) is used to plan radiotherapy treatments for patients with malignant or benign diseases. Eclipse TPS is used to plan external beam irradiation with photon, electron and proton beams, as well as for internal irradiation (brachytherapy) treatments.

COMPARISON OF TECHNOLOGICAL CHARACTERISTICS WITH THE PREDICATE DEVICE The modified device, referred to as the “subject device” throughout this summary, is release version v18.0 (version 18.0) of the Eclipse Treatment Planning System with additional software changes incorporated since the release version of the predicate device, version 16.1 (K201607).

At a high level, both the predicate device and the subject device are based on the same characteristics:  Both the subject device and the predicate provide software tools for planning the treatment of malignant or benign diseases with radiation.  They are computer-based software devices used by trained medical professionals to design and simulate radiation therapy treatments.  They are both capable of planning treatments for external beam irradiation with photon, electron, and proton beams, as well as for internal irradiation (brachytherapy) treatments.

The following differences exist between the software release versions of the subject and the predicate devices: The significant changes compared with the predicate device are as follows: Proton dose calculation changes:  Proton Monte Carlo optimization  Proton treatment time calculation  Proton fast particle generation Photon dose calculation and evaluation changes:  General SBRT normal tissue objective (NTO)  Enhanced leaf tip modeling  Speed improvement of GPU source model  FTDC Fourier transformation dose calculator improvements  Multi-criteria optimization (MCO) isodose line dragging Other changes:  UI support for treatment site  Brachytherapy dwell control improvements

See the full product information製品情報をすべて見るには

Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。

Start free 7-day access7日間無料で利用するLog inログイン

OFFICIAL FDA SOURCES

FDA Record and Public Document Status

Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。

Information reviewed:情報の確認日: August 18, 2026